Trace element supplementation modulates pulmonary infection rates after major burns: a double-blind, placebo-controlled trial

MM Berger, F Spertini, A Shenkin, C Wardle… - The American journal of …, 1998 - Elsevier
Infections remain the leading cause of death after major burns. Trace elements are involved
in immunity and burn patients suffer acute trace element depletion after injury. In a previous …

Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease

C Gabay, B Fautrel, J Rech, F Spertini, E Feist… - Annals of the …, 2018 - ard.bmj.com
Objectives Adult-onset Still’s disease (AOSD) is a rare systemic autoinflammatory disease;
its management is largely empirical. This is the first clinical study to determine if interleukin (IL)…

[HTML][HTML] MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis

…, GK Scadding, A Sheikh, F Spertini… - Journal of Allergy and …, 2016 - Elsevier
The selection of pharmacotherapy for patients with allergic rhinitis (AR) depends on several
factors, including age, prominent symptoms, symptom severity, control of AR, patient …

[HTML][HTML] Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose …

…, WR Ballou, MP Kieny, V Moorthy, F Spertini… - The Lancet infectious …, 2016 - thelancet.com
Background The ongoing Ebola outbreak led to accelerated efforts to test vaccine candidates.
On the basis of a request by WHO, we aimed to assess the safety and immunogenicity of …

[HTML][HTML] A Malaria Vaccine That Elicits in Humans Antibodies Able to Kill Plasmodium falciparum

P Druilhe, F Spertini, D Soesoe, G Corradin… - PLoS …, 2005 - journals.plos.org
Background Plasmodium falciparum merozoite surface protein 3 is a malaria vaccine
candidate that was identified, characterised, and developed based on a unique immuno-clinical …

Down‐regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α–kinoid

BR Lauwerys, E Hachulla, F Spertini… - Arthritis & …, 2013 - Wiley Online Library
Objective We developed interferon‐α–kinoid (IFN‐K), a drug composed of inactivated IFNα
coupled to a carrier protein, keyhole limpet hemocyanin. In human IFNα–transgenic mice, IFN…

Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial

F Spertini, R Audran, R Chakour, O Karoui… - The lancet Respiratory …, 2015 - thelancet.com
Background Tuberculosis remains one of the world's deadliest transmissible diseases despite
widespread use of the BCG vaccine. MTBVAC is a new live tuberculosis vaccine based …

Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen

…, O Leroy, G Corradin, P Druilhe, F Spertini - Infection and …, 2005 - Am Soc Microbiol
The C-terminal conserved region of Plasmodium falciparum merozoite surface protein 3 (MSP3)
is the trigger antigen of a protective immune response mediated by cytophilic antibodies…

Targeting of secretory IgA to Peyer's patch dendritic and T cells after transport by intestinal M cells

J Rey, N Garin, F Spertini, B Corthésy - The Journal of Immunology, 2004 - journals.aai.org
In addition to being instrumental to the protection of mucosal epithelia, secretory IgA (SIgA)
adheres to and is transported by intestinal Peyer’s patch (PP) M cells. The possible functional …

Adverse reactions to biologic agents and their medical management

O Boyman, D Comte, F Spertini - Nature Reviews Rheumatology, 2014 - nature.com
Biologic agents have substantially advanced the treatment of immunological disorders,
including chronic inflammatory and autoimmune diseases. However, these drugs are often …